| Name | Title | Contact Details |
|---|---|---|
Kinnari Patel |
President, Head of Research & Development and Chief Operating Officer | Profile |
Chris Stevens |
Chief Operating Officer | Profile |
Chantal Petit |
VP, Chief of Staff supporting the President/Head R&D/COO at Rocket Pharmaceuticals | Profile |
Mayo Pujols |
Executive Vice President and Chief Technical Officer | Profile |
Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.
Core Information Technology is a Salem, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases.
University Technologies International is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cutanix Corporation is a Franksville, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.